Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Inhibikase Therapeutics I...

    NASDAQ: IKT · Real-Time Price · USD
    1.60
    -0.05 (-3.03%)
    At close: Jun 27, 2025, 3:59 PM
    1.62
    0.93%
    After-hours: Jun 27, 2025, 05:50 PM EDT

    Inhibikase Therapeutics Statistics

    Share Statistics

    Inhibikase Therapeutics has 74.34M shares outstanding. The number of shares has increased by 861.21% in one year.

    Shares Outstanding

    n/a
    		 74.34M

    Shares Change (YoY)

    n/a
    		 861.21%

    Shares Change (QoQ)

    n/a
    		 3.23%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 45.51M

    Failed to Deliver (FTD) Shares

    n/a
    		 8,988

    FTD / Avg. Volume

    n/a
    		 6.6%

    Short Selling Information

    The latest short interest is 1.56M, so 2.09% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.56M

    Short % of Shares Out

    n/a
    		 2.09%

    Short % of Float

    n/a
    		 5.18%

    Short Ratio (days to cover)

    n/a
    		 12.37

    Valuation Ratios

    The PE ratio is -2.8 and the forward PE ratio is -3.4. Inhibikase Therapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -2.8

    Forward PE

    n/a
    		 -3.4

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.4

    PB Ratio

    n/a
    		 0.81

    P/FCF Ratio

    n/a
    		 -4.02

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Inhibikase Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 26.37, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 26.37

    Quick Ratio

    n/a
    		 26.37

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,834,659.07

    Employee Count

    n/a
    		 15

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 21.17% in the last 52 weeks. The beta is 0.94, so Inhibikase Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.94

    52-Week Price Change

    n/a
    		 21.17%

    50-Day Moving Average

    n/a
    		 1.97

    200-Day Moving Average

    n/a
    		 2.24

    Relative Strength Index (RSI)

    n/a
    		 35.37

    Average Volume (20 Days)

    n/a
    		 136,259

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -28.59M

    Net Income

    n/a
    		 -27.52M

    EBITDA

    n/a
    		 -27.49M

    EBIT

    n/a
    		 -27.52M

    Earnings Per Share (EPS)

    n/a
    		 -1.16
    Full Income Statement

    Balance Sheet

    The company has 56.49M in cash and 110.52K in debt, giving a net cash position of 56.38M.

    Cash & Cash Equivalents

    n/a
    		 56.49M

    Total Debt

    n/a
    		 110.52K

    Net Cash

    n/a
    		 56.38M

    Retained Earnings

    n/a
    		 -94.42M

    Total Assets

    n/a
    		 94.28M

    Working Capital

    n/a
    		 85.61M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -19.15M and capital expenditures 0, giving a free cash flow of -19.15M.

    Operating Cash Flow

    n/a
    		 -19.15M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -19.15M

    FCF Per Share

    n/a
    		 -0.81
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    IKT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for IKT is $8, which is 381.9% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $8

    Price Target Difference

    n/a
    		 381.9%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jun 30, 2023. It was a backward split with a ratio of 1:6.

    Last Split Date

    n/a
    		 Jun 30, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:6

    Scores

    Altman Z-Score

    n/a
    		 8.74

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist